Intellectual Property
Neuronascent continues to submit provisional, PCT and National patent applications for the composition and use of families of structures that promote neurogenesis and neuron regeneration as well as for neuroprotection and for psychiatric disorders. The following identifies the Issued, Expired, and patents Pending.
Patents Issued on lead families, both Composition and Use
- Issued by USPTO (3rdt and 4th) (Expires 11/2027 & 08/2028)
- Russia in 2011, S. Korea and China (limited claims) 2012, Australia and Canada 2013, Japan and Israel 2014 (all expired 09/19/2026)
- Lead AD/PD/CCDS (NNI-362) and neuropsychiatric/FXS (NNI-351) in US Expires 2027/2028
Extension of patents for lead candidates:
- METHODS AND COMPOSITIONS FOR LIPID FORMULATION OF
-
- LIPOPHILIC SMALL MOLECULE THERAPIES OF THE HETEROCYCLIC
- TYPE – US, Submitted 12/2023
- METHODS AND COMPOSITIONS FOR LIPID FORMULATION OF
-
- LIPOPHILIC SMALL MOLECULE THERAPIES OF THE HETEROCYCLIC
- TYPE – EU, Asia, Canada, Australia Pending, Submitted 06/2022
- Orphan Drug FDA-designation for Fragile X syndrome (NNI-351) (2023)
- Combination therapies provisional patent (Published 12/2023)
National Patent filing on second family, both Composition and Use (NNI-370-PD)
- Claims issued by USPTO (Expires 2028/2029)
- Japan and EU covering neurodegenerative disease reversing agent (allowed to expire)